FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022335753> ?p ?o ?g. }

• W2022335753 endingPage "1443" @default.
• W2022335753 startingPage "1437" @default.
• W2022335753 abstract "Objectives. The specific objective of the REDUCE trial was to evaluate the effect of low molecular weight heparin on the incidence and occurrence of restenosis in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Background. Unfractionated heparin and its low molecular weight fragments possess antiproliferative effects and have been shown to reduce neointimal smooth muscle cell migration and proliferation in response to vascular injury in experimental studies. Methods. The REDUCE trial is an international prospective, randomized, double-blind, multicenter study. Twenty-six centers in Europe and Canada enrolled 625 patients with single-lesion coronary artery obstructions suitable for PTCA. Three hundred six patients received reviparin as a 7,000-U bolus before PTCA, followed by 10,500 U as an infusion over 24 h and then twice-daily 3,500-U subcutaneous application for 28 days. The 306 patients in the control group received a bolus of 10,000 U of unfractionated heparin followed by an infusion of 24,000 U over 24 h. These patients then underwent 28 days of subcutaneous placebo injections. The primary end points were efficacy (defined as a reduction in the incidence of major adverse events [i.e., death, myocardial infaction, need for reintervention or bypass surgery]), absolute loss of minimal lumen diameter and incidence of restenosis during the observation period of 30 weeks after PTCA. Results. Using the intention to treat analysis for all patients, 102 (33.3%) in the reviparin group and 98 (32%) in the control group have reached a primary clinical end point (relative risk [RR] 1.04, 95% confidence interval [CI] 0.83 to 1.31, p = 0.707). Likewise, no difference in late loss of minimal lumen diameter was evident for both groups. Acute events within 24 h occurred in 12 patients (3.9%) in the reviparin group and 25 (8.2%) in the control group (RR 0.49, 95% Cl 0.26 to 0.92, p = 0.027) during or immediately after the initial procedure. In the control group, eight major bleeding complications occurred, and in the reviparin group, seven were observed within 35 days after PTCA. Conclusions. Reviparin use during and after coronary angioplasty did not reduce the occurrence of major clinical events or the incidence of angiographic restenosis over 30 weeks." @default.
• W2022335753 created "2016-06-24" @default.
• W2022335753 creator A5003060105 @default.
• W2022335753 creator A5015900652 @default.
• W2022335753 creator A5027985326 @default.
• W2022335753 creator A5034292214 @default.
• W2022335753 creator A5034363374 @default.
• W2022335753 creator A5055068378 @default.
• W2022335753 creator A5055225929 @default.
• W2022335753 creator A5056876246 @default.
• W2022335753 creator A5057323746 @default.
• W2022335753 creator A5060565487 @default.
• W2022335753 creator A5062210605 @default.
• W2022335753 creator A5063792624 @default.
• W2022335753 creator A5088049440 @default.
• W2022335753 date "1996-11-01" @default.
• W2022335753 modified "2023-10-12" @default.
• W2022335753 title "Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial)" @default.
• W2022335753 cites W1591002421 @default.
• W2022335753 cites W1965521253 @default.
• W2022335753 cites W1965632673 @default.
• W2022335753 cites W1968164572 @default.
• W2022335753 cites W1977798903 @default.
• W2022335753 cites W1989456091 @default.
• W2022335753 cites W2002155023 @default.
• W2022335753 cites W2011429978 @default.
• W2022335753 cites W2013095708 @default.
• W2022335753 cites W2020906145 @default.
• W2022335753 cites W2024323580 @default.
• W2022335753 cites W2033354476 @default.
• W2022335753 cites W2034487226 @default.
• W2022335753 cites W2040614895 @default.
• W2022335753 cites W2073741166 @default.
• W2022335753 cites W2073923473 @default.
• W2022335753 cites W2075535659 @default.
• W2022335753 cites W2078765684 @default.
• W2022335753 cites W2080653553 @default.
• W2022335753 cites W2084945610 @default.
• W2022335753 cites W2092972260 @default.
• W2022335753 cites W2094257962 @default.
• W2022335753 cites W2107392339 @default.
• W2022335753 cites W2127298401 @default.
• W2022335753 cites W2128781162 @default.
• W2022335753 cites W2130075870 @default.
• W2022335753 cites W2153935195 @default.
• W2022335753 cites W3022148767 @default.
• W2022335753 cites W4205312708 @default.
• W2022335753 cites W4293241248 @default.
• W2022335753 doi "https://doi.org/10.1016/s0735-1097(96)00343-9" @default.
• W2022335753 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8917255" @default.
• W2022335753 hasPublicationYear "1996" @default.
• W2022335753 type Work @default.
• W2022335753 sameAs 2022335753 @default.
• W2022335753 citedByCount "117" @default.
• W2022335753 countsByYear W20223357532012 @default.
• W2022335753 countsByYear W20223357532014 @default.
• W2022335753 countsByYear W20223357532016 @default.
• W2022335753 countsByYear W20223357532019 @default.
• W2022335753 countsByYear W20223357532020 @default.
• W2022335753 crossrefType "journal-article" @default.
• W2022335753 hasAuthorship W2022335753A5003060105 @default.
• W2022335753 hasAuthorship W2022335753A5015900652 @default.
• W2022335753 hasAuthorship W2022335753A5027985326 @default.
• W2022335753 hasAuthorship W2022335753A5034292214 @default.
• W2022335753 hasAuthorship W2022335753A5034363374 @default.
• W2022335753 hasAuthorship W2022335753A5055068378 @default.
• W2022335753 hasAuthorship W2022335753A5055225929 @default.
• W2022335753 hasAuthorship W2022335753A5056876246 @default.
• W2022335753 hasAuthorship W2022335753A5057323746 @default.
• W2022335753 hasAuthorship W2022335753A5060565487 @default.
• W2022335753 hasAuthorship W2022335753A5062210605 @default.
• W2022335753 hasAuthorship W2022335753A5063792624 @default.
• W2022335753 hasAuthorship W2022335753A5088049440 @default.
• W2022335753 hasBestOaLocation W20223357532 @default.
• W2022335753 hasConcept C126322002 @default.
• W2022335753 hasConcept C141071460 @default.
• W2022335753 hasConcept C142724271 @default.
• W2022335753 hasConcept C164705383 @default.
• W2022335753 hasConcept C168563851 @default.
• W2022335753 hasConcept C197934379 @default.
• W2022335753 hasConcept C203092338 @default.
• W2022335753 hasConcept C204787440 @default.
• W2022335753 hasConcept C27081682 @default.
• W2022335753 hasConcept C2775965419 @default.
• W2022335753 hasConcept C2776884760 @default.
• W2022335753 hasConcept C2777557582 @default.
• W2022335753 hasConcept C2778283817 @default.
• W2022335753 hasConcept C2778583881 @default.
• W2022335753 hasConcept C2780326628 @default.
• W2022335753 hasConcept C2992435398 @default.
• W2022335753 hasConcept C42219234 @default.
• W2022335753 hasConcept C43376680 @default.
• W2022335753 hasConcept C71924100 @default.
• W2022335753 hasConceptScore W2022335753C126322002 @default.
• W2022335753 hasConceptScore W2022335753C141071460 @default.
• W2022335753 hasConceptScore W2022335753C142724271 @default.
• W2022335753 hasConceptScore W2022335753C164705383 @default.
• W2022335753 hasConceptScore W2022335753C168563851 @default.

• next